EverGlade Insights Archives - EverGlade Consulting

EverGlade Insights

EverGlade Consulting

Unlocking Federal Opportunities for AI & Technology Innovators

Leave a Comment / AI, EverGlade Insights, Technology / By

Securing federal funding is more than a financial boost – it’s a strategic move that positions your company as a leader in innovation. EverGlade Consulting’s proven process helps small and medium-sized AI and tech firms navigate complex federal funding landscapes. Our process works because we focus on your business goals, not just technical details, ensuring […]

Unlocking Federal Opportunities for AI & Technology Innovators Read More »

Leveraging AI to Enhance Business Intelligence

Leveraging AI to Enhance Business Intelligence

Leave a Comment / DIU, EverGlade Insights, Time Sensitive / By

DOD’s New Initiative_AOI Solicitation Leveraging AI to Enhance Business Intelligence: The DoD’s New Initiative The Department of Defense (DoD) has identified a critical need to modernize business intelligence assessments to keep pace with evolving challenges in due diligence evaluations and industrial foreign influence analyses. To address this, the Defense Innovation Unit (DIU) has released an

Leveraging AI to Enhance Business Intelligence Read More »

ARPA-H PROSPR prolonging resilience

EverGlade Consulting Funding Alert: PROactive Solutions for Prolonging Resilience (PROSPR)

Leave a Comment / ARPA-H, EverGlade Insights / By

ARPA-H-SOL-25-125_Special_Notice ARPA-H’s PROSPR Program The Advanced Research Projects Agency for Health (ARPA-H) has announced the PROactive Solutions for Prolonging Resilience (PROSPR) initiative, an ambitious program designed to extend the healthspan of Americans by addressing the underlying causes of age-related health loss. By pioneering innovative interventions that target age-induced health deterioration, ARPA-H aims to revolutionize healthcare

EverGlade Consulting Funding Alert: PROactive Solutions for Prolonging Resilience (PROSPR) Read More »

PAHPA program funding

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness

Leave a Comment / BARDA, EverGlade Insights / By

Congress’s passage of a continuing resolution (CR) has averted a shutdown and provided temporary relief until late March. However, this short-term fix exposes significant gaps in public health and technology preparedness that demand immediate attention. As critical programs approach expiration and threats beyond the Pandemic and All-Hazards Preparedness Act (PAHPA) remain unresolved, lawmakers have a

After the CR: Funding Opportunities and Gaps in Pandemic Preparedness Read More »

Radiation & Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices

Development of Radiation/Nuclear Medical Countermeasures And Biodosimetry Devices

Leave a Comment / EverGlade Insights, NIAID, Time Sensitive / By

NIAID_Presolicitation_Notice_Rad_Nuc MCMs Overview of Solicitation The National Institute of Allergy and Infectious Diseases (NIAID), under the National Institutes of Health (NIH), has released a pre-solicitation notice for the development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices. This Broad Agency Announcement (BAA 75N93024R00020) is an invitation for innovators in the critical field of radiation emergency

Development of Radiation/Nuclear Medical Countermeasures And Biodosimetry Devices Read More »

ACTR Initiative clinical trials

Transforming Clinical Trials with the Advancing Clinical Trial Readiness (ACTR) Initiative

Leave a Comment / ARPA-H, EverGlade Insights / By

ARPA-H launches groundbreaking funding opportunity The Advancing Clinical Trial Readiness (ACTR) Initiative, spearheaded by ARPA-H’s Resilient Systems Office (RSO), aims to revolutionize clinical trials by developing a decentralized, efficient, and accessible infrastructure. Overview of Solicitation The ACTR Initiative is focused on creating tools, networks, and infrastructure to enable decentralized and on-demand clinical trials. By integrating

Transforming Clinical Trials with the Advancing Clinical Trial Readiness (ACTR) Initiative Read More »

ARPA-H health equity, technology, and biomedical research

Emerging Health Innovators (EHI) Initiative Proposer’s Day

Leave a Comment / ARPA-H, EverGlade Insights / By

ARPA-H-SN-25-119 (1) The Advanced Research Projects Agency for Health (ARPA-H) has launched the Emerging Health Innovators (EHI) Initiative, a transformative funding opportunity aimed at empowering early-career researchers and community-based innovators to revolutionize healthcare. To support this initiative, ARPA-H is holding a virtual Proposer’s Day on January 8th, 2025, from 11AM to 4PM EDT. Overview of

Emerging Health Innovators (EHI) Initiative Proposer’s Day Read More »

medical countermeasures for biodefense and infectious diseases

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease

Leave a Comment / EverGlade Insights, NIAID, NIH / By

HHS-NIH-NIAID-BAA2025-1 The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has released the Broad Agency Announcement (BAA) HHS-NIH-NIAID-BAA2025-1. This announcement presents an exciting opportunity for researchers, organizations, and industry leaders to contribute to critical biomedical and biodefense initiatives.

Omnibus Solicitation Seeks Medical Countermeasures for Biodefense and Emerging Infectious Disease Read More »

handheld diagnostic device

Assay Expansion for Chemical Diagnostic System

Leave a Comment / DTRA, EverGlade Insights / By

Assay-Expansion-for-Chemical-Diagnostics-System-SOO_Final The Defense Threat Reduction Agency’s Medical Diagnostics Branch (RD-CBMD) is driving innovation with its 2026 solicitation to expand the ChemDx platform. ChemDx is a handheld diagnostic device for rapid detection of chemical threats, such as nerve agents or certain pesticides, in blood from a finger prick. This effort seeks proposals from organizations interested in

Assay Expansion for Chemical Diagnostic System Read More »

drug-resistant bacterial infections

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

Leave a Comment / BARDA, EverGlade Insights / By

PBS+AMR+2025+SSN+-+Final The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens Read More »

anti-microbial

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials

Leave a Comment / DPA, EverGlade Insights / By

HHS+DPA+T3+RFI_Antimicrobials+-+Clean+copy+11-7-24+(002) The U.S. Department of Health and Human Services (HHS) Defense Production Act (DPA) Title III Program recently issued a Request for Information (RFI) aimed at strengthening the domestic production of anti-microbial products. This initiative seeks input from industry to assess current capacities and capabilities in producing essential anti-microbials critical for public health and national

HHS Defense Production Act (DPA) Title III Program’s RFI on Anti-Microbials Read More »

antimicrobial-resistant (AMR) pathogens and viruses

NIAID Omnibus Broad Agency Announcement (BAA)

Leave a Comment / EverGlade Insights, NIAID, Time Sensitive / By

Pre-solicitation_Notice_-_BAA2025-1_Final Overview of Solicitation The upcoming 2026 Omnibus Broad Agency Announcement (BAA) is from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS). NIAID’s mission centers on understanding, treating, and preventing infectious, immunologic, and allergic diseases. Through

NIAID Omnibus Broad Agency Announcement (BAA) Read More »

Scroll to Top

EverGlade Consulting

2025 Proposal Package

Submit 1 proposal, SAVE UP TO 20% Submit 2 proposals, SAVE UP TO 60% Submit 3 proposals, SAVE UP TO 73% Submit 4 proposals, SAVE UP TO 80%
Inquire Now